IntraBio says rare disease drug passes Phase 3, will seek FDA approval

IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...